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total number of customers who patronized the pharma-
cies during the study period. The mean respondents’ sat-
isfaction score was 4.24 (SD 0.52) out of a maximum
possible score of 5.0. Most respondents also supported
the suggestion of providing such services on a wider
scale. However, half the respondents indicated that they
were unwilling to pay for the professional services. CON-
CLUSION: The customers interviewed were satisfied
with the pharmaceutical care services provided but their
responses to paying for the services were less positive.
However, due to the limited time and small number of
participants in this project, a definite conclusion cannot
be drawn as to whether similar results would be obtained
if there were greater awareness by the public.
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INTRODUCTION: Sepsis is a pervasive problem world-
wide, and typically affects persons with significant under-
lying diseases, immunosupression, or major trauma. De-
spite recent advances in therapy and intensive care
medicine, mortality rates have remained essentially un-
changed over the past decade. Furthermore, sepsis is
poorly defined, usually incorporating septicemia, SIRS
and severe sepsis. OBJECTIVE: The purpose of this
study was to determine the outcomes and utilization of
hospital and ICU days in patients with severe sepsis.
METHODS: This evaluation was conducted as part of a
prospective, multi-center, cohort study (“Sepsis Longi-
tudinal Epidemiological Clinical Outcomes Tracking”
[SELECT] registry) in 398 patients with severe sepsis of
presumed infectious origin recruited through 45 ICU
units across the US. For each ICU admission, patient de-
mographic, ICU length of stay (LOS), hospital LOS and
hospital discharge status (dead or alive) was collected. In
addition, data concerning source of infection, comorbidi-
ties and treatments were also collected. RESULTS: In pa-
tients with severe sepsis, the most common comorbidities
were CVD (38%), respiratory failure (36%) and diabetes
(26%), and the majority were admitted from home
(73%). The most common sources of infection were pul-
monary (44%) and abdominal (23%). Overall mortality
in patients with severe sepsis was 42%. ICU survivors
had significantly longer mean hospital LOS (29 vs. 18
days, P  0.01) and ICU LOS (18 vs. 13 days, P  0.01)
compared to non-survivors. Both groups received similar
treatment. CONCLUSION: Based on these observations,
severe sepsis of presumed infectious origin is associated
with a high mortality rate and significant utilization of
hospital resources.
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THE BURDEN OF RESPIRATORY SYNCTIAL 
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OBJECTIVES: To quantify the burden to the US of RSV
associated hospitalizations using a new (October, 1996)
ICD-9 code for RSV bronchiolitis and two established
RSV codes. METHODS: We conducted a retrospective
analysis of two recent federal databases. The 1997 Na-
tional Hospital Discharge Survey (NHDS) was used to
identify the number of discharges among children under
age 5 with a primary diagnosis of RSV bronchiolitis
(ICD-9 466.11); RSV pneumonia (ICD 480.1) and RSV
(ICD-9 079.6); patient demographics; length of stay
(ALOS); and expected payment source. NHDS formulas
were used to estimate standard errors, normal distribu-
tions were assumed for the calculation of 95% CIs. Mean
charges were generated from the 1996 HCUP-3 NIS and
inflated to 1997 dollars using the Medical Care compo-
nent of the CPI (1.028). RESULTS: In 1997 an estimated
110,000 RSV-associated discharges occurred among chil-
dren under age five. RSV-bronchiolitis accounted for
84% [95% CI, 71%–97%] of RSV discharges; while
RSV pneumonia accounted for 15% [95% CI, 1%–
19%]. ALOS for RSV bronchiolitis was 3.5 days [95%
CI, 3.0–4.0]; 4.3 days [95% CI, 3.2–5.4] for RSV pneu-
monia; and 2.8 [95% CI, 0.3–5.2] for RSV. Mean hospi-
tal charges were $9572 for infants six months and
younger and $9056 for those under age one. 81%
[95%CI, 68%–94%] of children discharged with RSV
were under age one. CONCLUSIONS: Previous studies
may have underestimated the burden of RSV. Estimated
total 1997 hospital charges for RSV in children under age
5 were over $750 million with 75% ($580 million) for
RSV bronchiolitis. Medicaid insured 50% and private in-
surers covered 39% of these discharges. The actual burden
may be larger since RSV infections may be undercoded
and this analysis was restricted to primary diagnoses.
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Even though it is widely recognised that influenza is a se-
rious disease that causes significant consequences in
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terms of morbidity and mortality, implying considerable
healthcare costs and loss of productivity, there is a lack
of data about the economic impact of an influenza epi-
demic in Italy. OBJECTIVES: The aim of this study was
to estimate the social cost of a normal influenza epidemic
in Italy using a generic algorithm for influenza outbreak
and treatment. METHODS: Referring to the demo-
graphic characteristics of the population, to the pub-
lished literature and to the epidemiological data (influ-
enza season 1998/99), a simulation of the impact of a
real influenza epidemic was run. The health service use
and unit costs were estimated from standard data
sources. RESULTS: The average direct costs of influenza
per person in Italy were lit. 68,000 ($US 36) for the over-
all population, and lit. 155,000 ($_S 82.26) for a high-
risk patient; the average indirect costs of influenza per
working patient were lit. 569,000 ($US 301.97). Hence,
the total cost of a case of influenza in Italy was about lit.
637,000 ($US 338). In general, around 90% of total
costs consisted of indirect costs. Costs are sensitive to
changes in the rate of hospitalization and to changes in
the proportion of the active population. CONCLU-
SIONS: Cost-of-illness studies should be “observational”
to reflect the real world. Nevertheless, if relevant data are
not available, a suitable model which uses reliable data
can give consistent estimates of the cost of influenza in It-
aly. This kind of model may help decision-makers
heighten awareness of the burden of influenza and design
prevention and treatment strategies.
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US estimates show that 1.7 million annually develop
pressure ulcers incurring costs of $8.5 billion. Leg ulcers
affect 2.5 million persons in the US and their prevalence
will likely rise as the population ages. OBJECTIVES: We
determined the average costs and frequencies of prescrip-
tion, physician and inpatient hospital claims for four di-
agnostic categories of skin ulcers from 1994 through
1998, including ulcers of lower limbs (ICD-9 code
707.1), pressure ulcers (ICD-9 code 707.0), venous leg
ulcers (ICD-9 codes 454.0/454.2) and other chronic ul-
cers (ICD-9 codes 707.8/707.9). METHODS: A retro-
spective review of the New Mexico Medicaid (NMM)
Drug Utilization Review (DUR) database was conducted.
Data on frequency of hospital admissions, physician vis-
its, and medications, as well as related costs, were ana-
lyzed. Prescription claims were not specific to ulcers, and
included the top ten concomitant drugs. RESULTS:
Mean annual hospital costs per patient ranged from
$8671.48 (SD  $444.10) for other chronic ulcers to
$15,733.16 (SD  $482.14) for venous leg ulcers. Mean
annual hospital admissions per patient ranged from 1.25
(SD  0.02) for other chronic ulcer to 1.50 (SD  0.06)
for venous leg ulcers. Mean annual physician costs per
patient ranged from $111.09 (SD  $14.16) for other
chronic ulcers to $196.08 (SD  $20.64) for ulcers of the
lower limbs. Mean annual physician visits per patient
ranged from 2.05 (SD  0.16) for other chronic ulcers to
3.63 (SD  0.32) for ulcers of the lower limb. Mean an-
nual prescription cost per patient was $4179.18 (2461
patients). CONCLUSIONS: Costs from the perspective
of the NMM program are substantial. Assessment of the
cost-effectiveness of various treatments is warranted.
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Antibiotic treatment of respiratory tract infection (RTI)
has been evaluated in many clinical trials, but little is
known about its effectiveness (efficacy in real life condi-
tions) and costs. OBJECTIVE: To measure the effective-
ness, side effects and costs associated with the use of var-
ious antibiotics in the ambulatory treatment of RTI in
adults. METHODS: Patients aged 18 were recruited by
community pharmacists. They were considered for inclu-
sion if they reported being treated for an RTI and re-
ceived a new prescription for one of the following antibi-
otics: amoxicillin, amoxicillin/clavulanate, azithromycin,
cefaclor, cefuroxime, ciprofloxacin, clarithromycin or
erythromycin. Presence of symptoms, side effects and re-
source utilization were reported in a self-administered
questionnaire covering the first 14 days after treatment
was initiated. A follow-up call at 28 days completed the
data collection. Resource utilization considered included
initial antibiotic, physician and pharmacist services, other
medications (prescribed and OTC), and alternate antibi-
otic when required. RESULTS: Of 989 patients recruited,
777 returned their questionnaire (79%). At day 7, 33%
of patients reported having symptoms. This proportion
did not vary according to the antibiotic even when con-
trolling for the type of RTI (URTI vs. LRTI) (2, P 
0.05). Diarrhea was reported by 17%, nausea by 11%
and abdominal pain by 10% of patients. Erythromycin
had the largest proportion of patients reporting a GI side
effect (53%). Average cost per episode varied between
$34 and $89 (Canadian). Lower costs were seen for pa-
tients started with amoxicillin or erythromycin. The
highest cost was seen in patients started with cefaclor/
cefuroxime. CONCLUSION: Effectiveness was not de-
pendent on the antibiotic selected at the start of treat-
ment. Occurrence of side effects was relatively high.
